市场调查报告书
商品编码
1396543
熊去氧胆酸市场 - 按类型(合成、生物)、应用(胆结石、原发性胆汁性胆管炎)、模式(内部、合约製造)、用途(人类、兽医)、全球预测,2023 - 2032Ursodeoxycholic Acid Market - By Type (Synthetic, Biological), Application (Gall Stones, Primary Biliary Cholangitis), Mode (In-house, Contract Manufacturing), Use (Human, Veterinary), Global Forecast, 2023 - 2032 |
在医学研究和诊断的进步以及对有效胆汁酸治疗的需求不断增长的推动下,2023年至2032年全球熊去氧胆酸市场规模将以10.1%的CAGR扩大。随着这些进步增强了对肝臟疾病的理解和治疗,熊去氧胆酸(通常称为熊二醇)将成为关键的治疗选择。其功效得到认可,市场受益于人们对熊二醇在解决胆汁酸相关疾病方面的作用的认识和接受度的提高,从而扩大了其市场规模和药物相关性。
本公司积极参与与熊去氧胆酸相关的研发活动,并取得熊二醇药物的必要许可。这一策略重点透过确保扩大熊去氧胆酸药物的供应、满足对有效治疗不断增长的需求以及促进解决胆汁酸相关疾病的製药进步来加强熊去氧胆酸产业。例如,2021 年,Strides Pharma Science 的全资子公司 Strides Pharma Global 的 Ursodiol 胶囊 USP(300 毫克)获得美国食品药物管理局 (USFDA) 的批准。
熊去氧胆酸市场规模根据模式、应用和地区进行细分。
到 2032 年,由于製药业越来越依赖外包来简化生产流程并确保成本效益,合约製造部门将占据相当大的收入份额。合约製造提供了灵活性和专业知识,使製药公司能够满足对熊去氧胆酸不断增长的需求。合约製造业务专注于优化资源和提高生产能力,将成为满足市场对熊去氧胆酸供应不断变化的需求的关键解决方案。
到 2032 年,胆结石应用领域将显着增强熊去氧胆酸产业前景,因为该化合物具有溶解胆结石的功效,提供了一种非手术替代方案。随着胆结石相关疾病的日益流行,熊去氧胆酸将成为关键的治疗解决方案。随着医疗保健提供者选择保守方法,胆结石应用领域将成为市场的关键贡献者,满足对有效和微创治疗方案不断增长的需求。
欧洲从 2023 年到 2032 年将出现显着的CAGR,原因包括该地区肝臟疾病发病率不断上升、医疗基础设施健全以及针对胃肠道疾病采取积极措施等。人们对以熊去氧胆酸为基础的治疗方法的认识和采用不断提高,促进了该地区的突出地位。随着医疗保健的进步和患者人数的增加,欧洲将成为市场的重要贡献者,确保在不断发展的熊去氧胆酸产业格局中占据重要地位。
Global Ursodeoxycholic Acid Market size will expand at a 10.1% CAGR from 2023 to 2032, propelled by advancements in medical research and diagnostics coupled with a growing demand for effective bile acid-based treatments. As these advancements enhance the understanding and treatment of liver disorders, ursodeoxycholic acid, commonly known as ursodiol, will stand out as a pivotal therapeutic option. Recognized for its efficacy, the market benefits from increasing awareness and acceptance of Ursodiol's role in addressing bile acid-related disorders, bolstering its market size and pharmaceutical relevance.
Companies are actively involved in research and development activities associated with ursodeoxycholic acid, obtaining necessary permissions for ursodiol medications. This strategic focus reinforces the ursodeoxycholic acid industry by ensuring an expanded supply of ursodiol medicines, meeting the growing demand for effective treatments, and fostering pharmaceutical advancements in addressing bile acid-related disorders. For instance, in 2021, Strides Pharma Global, a fully owned subsidiary of Strides Pharma Science, secured approval from the United States Food and Drug Administration (USFDA) for Ursodiol Capsules USP, 300 mg.
The ursodeoxycholic acid market size is segmented based on mode, application, and region.
The contract manufacturing segment will capture a substantial revenue share through 2032, driven by the pharmaceutical industry's increasing reliance on outsourcing to streamline production processes and ensure cost-effectiveness. Contract manufacturing offers flexibility and expertise, enabling pharmaceutical companies to meet the growing demand for ursodeoxycholic acid. With a focus on optimizing resources and enhancing production capabilities, the contract manufacturing segment will stand out as a pivotal solution in satisfying the market's evolving needs for ursodeoxycholic acid supply.
The gallstones application segment will significantly strengthen the ursodeoxycholic acid industry outlook through 2032 due to the compound's efficacy in dissolving gallstones, offering a non-surgical alternative. With an increasing prevalence of gallstone-related conditions, ursodeoxycholic acid will emerge as a key therapeutic solution. As healthcare providers opt for conservative approaches, the gallstones application segment will become a pivotal contributor to the market, catering to the rising demand for effective and minimally invasive treatment options.
Europe will register a notable CAGR from 2023 to 2032, attributed to factors such as the region's increasing incidence of liver disorders, a robust healthcare infrastructure, and proactive measures to address gastrointestinal diseases. Growing awareness and adoption of ursodeoxycholic acid-based treatments contribute to the region's prominence. With a combination of healthcare advancements and a rising patient population, Europe will emerge as a significant contributor to the market, ensuring a substantial presence in the evolving ursodeoxycholic acid industry landscape.